Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript

Aethlon Medical held its 2026 virtual annual meeting of stockholders on October 1, with voting opened on the matters presented. CEO/CFO James Frakes chaired the meeting, joined by VP Controller Michele Bombardiere and outside counsel Jennifer Trowbridge as inspector of election. The provided excerpt contains no financial results, operating update, guidance, or material corporate action.

Analysis

There is no incremental clinical, regulatory, financing, or operating disclosure here to alter AEMD’s fundamental valuation. The relevant signal is governance-related: the CEO simultaneously holding CFO, chief accounting officer, secretary, and director roles concentrates financial-control and succession risk in a micro-cap development-stage biotech. That structure can widen the discount applied by institutional investors and makes any future capital raise more sensitive to credibility, audit quality, and board independence.

Near term, this is not a standalone trading catalyst; liquidity rather than fundamentals is likely to determine the immediate share-price response. Over the next 1-3 months, the investable event is any subsequent disclosure on cash runway, ATM usage, reverse-split authorization, trial enrollment, FDA interactions, or a permanent finance-leadership appointment. In the 6-18 month window, absent independently verifiable clinical progress, dilution risk is likely to dominate upside optionality because platform-biotech operating costs generally require repeated external financing.

Contrarianly, concentrated management roles are not necessarily evidence of misconduct at a small issuer; they may reflect cost containment. But the market should not assign value to governance optics alone: a re-rating requires a measurable catalyst such as clinical data, a funded partnership, or non-dilutive capital. No directional trade is warranted from this meeting transcript alone.

Key Decisions for Investors

• No new AEMD position on this event; treat any volume-driven move as non-fundamental unless accompanied by an SEC filing detailing cash balance, financing terms, or clinical/regulatory milestones.
• For existing long exposure, reduce or hedge into rallies not supported by trial data or financing improvement; reassess if quarterly cash runway falls below 12 months or ATM/dilutive issuance accelerates.
• Create an event alert for a CFO/CAO separation, independent director additions, reverse-split proposal, or trial update. A credible finance hire and at least 18 months of funded runway would reduce governance and dilution discounts; a going-concern warning or discounted financing would falsify any constructive view.
• Avoid shorting solely on governance concentration given micro-cap borrow constraints and binary clinical headline risk; if bearish exposure is required, size it as a catalyst trade only after a disclosed financing or adverse clinical/regulatory development.